SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Introgen Therapeutics
INGN 7.040-4.5%Nov 6 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jibacoa who wrote (575)10/18/2006 9:03:50 AM
From: zeta1961Read Replies (1) of 802
 
Introgen plans to initiate interim efficacy analyses of its ADVEXIN phase 3 clinical trials within the next quarter, and report the results to FDA later in 2007. Introgen expects head and neck cancer regulatory filings in the US and EU to be completed within 2007.

No wonder the shorts are having a blast(for several years now).. filing is 3 years past guidance and counting..

Disclosure: still long and yawning
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News